Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 1, 2005

In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent

  • Jean-Pierre Knapp and Wolfgang Herrmann

Abstract

Lipoprotein(a) (Lp(a)) is considered an independent risk factor for atherosclerotic heart and circulatory diseases. The unique, polymorphic character of Lp(a) is based on its apolipoprotein(a) (apo(a)), which has remarkable structural analogies with plasminogen, an important protein for fibrinolysis. The formation of plasmin from plasminogen is a fundamental step in the dissolution of fibrin. Repression of this step may lead to a deceleration of fibrinolysis.

It has been suggested that Lp(a) has antifibrinolytic properties through apo(a) and that the apo(a)-size polymorphism has a distinct influence on the prothrombotic properties of Lp(a). However, the results on this topic are controversial. Therefore we used a standardized in vitro fibrinolysis model to provide further information on the influence of Lp(a) on plasmin formation. Monitoring the time-course of plasmin formation, we investigated the inhibition of plasmin formation through dependence on Lp(a), respectively, free apo(a) concentration. Furthermore, we investigated the influence of three Lp(a)/apo(a) phenotypes (22KLp(a), 22 kringle-4 repeats; 30KLp(a), 30 kringle-4 repeats; 35KLp(a), 35 kringle-4 repeats).

Adding varying amounts of Lp(a) to our model, we observed that the rate of plasmin formation was inversely related to the Lp(a) concentration. At 0.1 µmol/l 30KLp(a), for example, the plasmin formation was reduced by 12.7% and decreased further by 40.7% at 0.25 µmol/l Lp(a). A similar but more distinct effect was observed when free 30Kapo(a) was added to the model (25.3% at 0.1 µmol/l vs. 59.3% at 0.25 µmol/l).

Comparing the antifibrinolytic influence of different apo(a) phenotypes we found that the reduction of plasmin generation advanced with the size of apo(a). At 0.1 µmol/l Lp(a) the reduction of the plasmin formation increased in the order 22KLp(a), 30KLp(a) and 35KLp(a) from 3.7% to 10.7% and 22.3%, respectively. Experiments with different phenotypes of free apo(a) showed similar results (0.5 µmol/l: 22Kapo(a), 56.4% vs. 30KLp(a), 80.4%).

Summarizing these results, our study indicates a distinct interrelation of Lp(a)/apo(a) phenotype and concentration with the formation of plasmin. From the antifibrinolytic Lp(a)/apo(a) effect in vitro it may be hypothesized that Lp(a)/apo(a) also has an inhibitory influence on in vivo fibrinolysis.


Corresponding author: Prof. Dr. Wolfgang Herrman, Department of Clinical Chemistry, Central Laboratory, Saarland Medical School, Kirrbergerstr., Geb. 57, 66421 Homburg/Saar, Germany. Phone:+49-6841-16-23070, Fax: +49-6841-16-23109, E-mail:

References

1 Berg K. A new serum type system in man – the Lp system. Acta Pathol Micribiol Scand 1963; 59:369–82.10.1111/j.1699-0463.1963.tb01808.xSearch in Google Scholar

2 Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74:758–65.10.1161/01.CIR.74.4.758Search in Google Scholar

3 Herrmann W, Hanf S, Schmidt H, Kostner GM. Lp(a) – ein besonderes Lipoprotein mit atherogener Wirkung. Z Klin Med 1987; 42:1333–6.Search in Google Scholar

4 Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990; 301:1248–51.10.1136/bmj.301.6763.1248Search in Google Scholar

5 Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; 335:1360–3.10.1016/0140-6736(90)91242-3Search in Google Scholar

6 Kark JD, Sandholzer C, Friedlander Y, Utermann G. Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis 1993; 98:139–51.10.1016/0021-9150(93)90124-DSearch in Google Scholar

7 Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997; 17:239–45.10.1161/01.ATV.17.2.239Search in Google Scholar

8 Koschinsky ML, Marcovina SM. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res 1997; 27:14–23.10.1007/BF02827238Search in Google Scholar

9 Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998; 82:57U–66U.10.1016/S0002-9149(98)00954-0Search in Google Scholar

10 Cambillau M, Simon A, Amar J, Giral P, Atger V, Segond P, et al. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. The PCVMETRA Group. Arterioscler Thromb 1992; 12:1346–52.10.1161/01.ATV.12.11.1346Search in Google Scholar

11 Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19:792–802.10.1016/0735-1097(92)90520-WSearch in Google Scholar

12 Nowak-Gottl U, Schobess R, Kurnik K, Schwabe D, Fleischhack G, Junker R. Elevated lipoprotein(a) concentration is an independent risk factor of venous thromboembolism. Blood 2002; 99:3476–7.10.1182/blood-2002-01-0100Search in Google Scholar

13 Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10:672–9.10.1161/01.ATV.10.5.672Search in Google Scholar

14 Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue- type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb 1991; 11:629–38.10.1161/01.ATV.11.3.629Search in Google Scholar

15 Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997; 100:1493–500.10.1172/JCI119671Search in Google Scholar

16 Gazzaruso C, Geroldi D, Garzaniti A, Falcone C, Fratino P, Finardi G, et al. Apolipoprotein(a) phenotypes as genetic markers of coronary atherosclerosis severity. Int J Cardiol 1998; 64:277–84.10.1016/S0167-5273(98)00050-3Search in Google Scholar

17 Hervio L, Chapman MJ, Thillet J, Loyau S, Angles-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 1993; 82:392–7.10.1182/blood.V82.2.392.bloodjournal822392Search in Google Scholar

18 Armstrong VW, Harrach B, Robenek H, Helmhold M, Walli AK, Seidel D. Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. J Lipid Res 1990; 31:429–41.10.1016/S0022-2275(20)43165-7Search in Google Scholar

19 Halvorsen S, Skjonsberg OH, Berg K, Ruyter R, Godal HC. Does Lp(a) lipoprotein inhibit the fibrinolytic system? Thromb Res 1992; 68:223–32.10.1016/0049-3848(92)90080-TSearch in Google Scholar

20 Mao SJ, Tucci MA. Lipoprotein(a) enhances plasma clot lysis in vitro. FEBS Lett 1990; 267:131–4.10.1016/0014-5793(90)80306-4Search in Google Scholar

21 Liu J, Harpel PC, Gurewich V. Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. Biochemistry 1994; 33:2554–60.10.1021/bi00175a026Search in Google Scholar PubMed

22 Testa R, Marcovina SM. The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels. Int J Clin Lab Res 1999; 29:128–32.10.1007/s005990050077Search in Google Scholar

23 Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28:2370–4.10.1021/bi00432a004Search in Google Scholar

24 Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996; 98:2414–24.10.1172/JCI119055Search in Google Scholar

25 Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH. Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest 1996; 97:858–64.10.1172/JCI118487Search in Google Scholar

26 Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996; 16:905–11.10.1161/01.ATV.16.8.905Search in Google Scholar

27 Kostner KM, Huber K, Stefenelli T, Rinner H, Maurer G. Urinary apo(a) discriminates coronary artery disease patients from controls. Atherosclerosis 1997; 129:103–10.10.1016/S0021-9150(96)06011-XSearch in Google Scholar

28 Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992; 38:2244–8.10.1093/clinchem/38.11.2244Search in Google Scholar

29 Trenkwalder E, Gruber A, Konig P, Dieplinger H, Kronenberg F. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int 1997; 52:1685–92.10.1038/ki.1997.503Search in Google Scholar PubMed

30 Mooser V, Marcovina SM, Wang J, Hobbs HH. High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay. Clin Genet 1997; 52:387–92.10.1111/j.1399-0004.1997.tb04358.xSearch in Google Scholar PubMed

31 Herrmann W, Quast S, Wolter K, Eger H, Kießig ST, Hahmann H, et al. Determination of free apo(a) in serum by immunoassay and its significance for risk assessment in patients with CAD. Clin Chem Lab Med 1999; 37:21–8.10.1515/CCLM.1999.003Search in Google Scholar PubMed

32 Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992; 360:670–2.10.1038/360670a0Search in Google Scholar

33 Scanu AM, Miles LA, Fless GM, Pfaffinger D, Eisenbart J, Jackson E, et al. Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). Evidence for the dominant role of kringle 4(37). J Clin Invest 1993; 91:283–91.10.1172/JCI116182Search in Google Scholar

34 Biemond BJ, Friederich PW, Koschinsky ML, Levi M, Sangrar W, Xia J, et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997; 96:1612–5.10.1161/01.CIR.96.5.1612Search in Google Scholar

35 Sangrar W, Gabel BR, Boffa MB, Walker JB, Hancock MA, Marcovina SM, et al. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry 1997; 36:10353–63.10.1021/bi962433dSearch in Google Scholar

36 Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments. J Biol Chem 1997; 272:11079–87.10.1074/jbc.272.17.11079Search in Google Scholar

37 Sattler W, Kostner GM, Waeg G, Esterbauer H. Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins. Biochim Biophys Acta 1991; 1081:65–74.10.1016/0005-2760(91)90251-CSearch in Google Scholar

38 Fless GM, ZumMallen ME, Scanu AM. Isolation of apolipoprotein(a) from lipoprotein(a). J Lipid Res 1985; 26:1224–9.10.1016/S0022-2275(20)34270-XSearch in Google Scholar

39 Kang C, Dominguez M, Loyau S, Miyata T, Durlach V, Angles-Cano E. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol 2002; 22:1232–8.10.1161/01.ATV.0000021144.87870.C8Search in Google Scholar

40 Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 1996; 125:53–61.10.1016/0021-9150(96)05844-3Search in Google Scholar

41 Kottke BA. Problems in the measurement of Lp(a) (millimoles per liter versus milligrams percent). J Am Coll Cardiol 2001; 38:1584–5.10.1016/S0735-1097(01)01541-8Search in Google Scholar

42 Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992; 12:1214–26.10.1161/01.ATV.12.10.1214Search in Google Scholar

43 Jurgens G, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995; 26:1841–8.10.1161/01.STR.26.10.1841Search in Google Scholar PubMed

44 Farrer M, Game FL, Albers CJ, Neil HA, Winocour PH, Laker MF, et al. Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb 1994; 14:1272–83.10.1161/01.ATV.14.8.1272Search in Google Scholar

Received: 2004-4-8
Accepted: 2004-7-8
Published Online: 2005-6-1
Published in Print: 2004-9-1

© Walter de Gruyter

Downloaded on 5.3.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2004.205/html
Scroll to top button